Andere talen Shanghai Junshi Biosciences Co., Ltd.

Aandelen

1877

CNE100003FF7

Farmaceutische producten

Beurs gesloten - Hong Kong S.E. Andere beurzen 09:08:17 13-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,10 ^HKD	-3,53%		-1,95%	-32,61%

29/11	Shanghai Junshi Biosciences Co, Ltd. Kondigt aan dat Meng Anming ontslag neemt als onafhankelijk niet-uitvoerend bestuurder en lid van het Strategisch Comité	CI
29/11	Teplizumab-injectie van Junshi Biosciences opgenomen in de geneesmiddelenverzekeringscatalogus van China voor 2025; aandelen stijgen met 6%	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Meng Anming as Independent Non-Executive Director and Member of the Strategic Committee	29/11
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong	29/11
Junshi Biosciences' Teplizumab Injection Included in China's 2025 Drug Insurance Catalog; Shares Up 6%	29/11
Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India	28/11
Junshi Bio Gets License to Develop Anti-Tumor Medication, Shares Rise 4%	20/11
Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator	18/11
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab	16/11
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab	16/11
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	29/10
Shanghai Junshi Biosciences Co., Ltd. Announces Demise of Dr. Shen Jingkang, Independent Non-Executive Director, Member of the Audit Committee and Member of the Strategic Committee	23/10
Shanghai Junshi Biosciences Gets Approval to Market Immunotherapy Drug in Hong Kong, China	16/10
Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR	15/10
Shanghai Junshi Biosciences' Cholesterol Drug Gets NDA from NMPA; Shares Down 5%	14/10
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection	13/10
Junshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%	27/09
Junshi Biosciences Gets Nod to Trial WJ47156 Tablets as Tumor Drug; Shares Soar 10%	27/09
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial	26/09
Junshi Biosciences' Cancer Drug Gets Approval for 2 Indications from European Commission	25/09
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab	25/09
Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab	24/09
Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback announced on September 10, 2023, has closed with 815,871 shares, representing 0.08% for CNY 30.88 million.	10/09
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	10/09
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates	02/09
Hong Kong Stocks Retreat to Start Week in Red Following Weak Manufacturing, Corporate Results	02/09
Shanghai Junshi Biosciences' Losses Shrink 35% in H1 as Revenue Jumps 17%	02/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shanghai Junshi Biosciences Co., Ltd.

Aandelen

1877

CNE100003FF7

Farmaceutische producten

Andere talen

Filters